Gemcitabine-induced thrombotic microangiopathy.
Thrombotic microangiopathy (TMA) is a microvascular occlusive disorder characterised by platelet aggregation, thrombocytopenia and end-organ damage. It is commonly idiopathic, although several drug classes, including cytotoxic chemotherapy, have been implicated. Several of cases of gemcitabine-induced TMA have been documented with incidence likely to increase with the escalating use of gemcitabine. We report the cases of two patients who developed TMA while on gemcitabine chemotherapy.
Cancer and Palliative Care Services, Toowoomba Health Service, Toowoomba, Queensland, Australia.
J
J
Richmond
P
P
Gilbar
E
E
Abro
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D057049:Thrombotic Microangiopathies / Q000139:chemically induced* / Q000175:diagnosis*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine
chemotherapy; gemcitabine; thrombotic microangiopathy